Dyax Corp. Announces Funded Research Agreement with Trubion Pharmaceuticals Inc. for Discovery of Therapeutic Proteins
09 Oct 2006 -
Dyax Corp. has entered into a non-exclusive agreement with Trubion Pharmaceuticals Inc. (Trubion) in the fields of protein therapeutics and diagnostics discovery. Under the agreement, Dyax will utilize its proprietary phage display libraries for the discovery of compounds that bind with high affinity and specificity to Trubion's targets in the oncology and inflammation area. Dyax will receive upfront
and FTE payments from Trubion, as well as technical and development milestone payments and royalties on net sales of any products that may result from Trubion's development and commercialization of binding regions from Dyax's libraries. The agreement also provides Trubion with an option to license Dyax's proprietary phage display libraries.
Additional information
Dyax Corp. Cambridge, MA, United States of America
Top
Contact
Print version
PDF version
Send article
RSS-Feed
